BeiGene (HKG:6160, SHA:688235) granted options to three grantees to subscribe for an aggregate of 3,754 American Depositary Shares (ADSs) on Aug. 30, a Thursday bourse filing said.
The options, which were granted under a 2016 share option and incentive plan, are exercisable at $198.37 per ADS for a period of 10 years.
The company, on the same day, granted a total of 66,829 restricted share unit (RSUs) to 179 Grantees under the same scheme. The RSUs represent 868,777 underlying shares, representing around 0.06% of the company's total issued share capital.
Following the grant of the options and RSUs, the drug company will have 81,050,878 underlying shares available for future grants under the award plan.
Hong Kong-listed shares of the company closed nearly 3% higher on Thursday.
Price (HKD): $115.10, Change: $+2.9, Percent Change: +2.58%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.